The REDMO Magazine is now available.
One more year, REDMO has continued to work UNSTOPPABLE thanks to the significant increase in bone marrow donors that has been in our country. In total they are more than 240,000!
Do you want to know the latest news about bone marrow donation and about our activity? You can do it in the REDMO magazine of 2016 in which you will find diverse articles.
Read it online (available in Spanish):
You can also dowload it HERE.
Josep Carreras raises more than three million euros for the fight against leukaemia in the 22nd TV Gala in Germany.
The Spanish Ministry of Economy, Industry and Competitivity has a State programme of grants for funding and encouraging the continuity of doctors with an outstanding scientific and technological record. The purpose of these awards is to give continuity to the aims of the research intensification, incorporation and promotion programme, known as ‘Programa I3’.
‘Programa I3’ recognises those researchers who have benefitted from a Ramon i Cajal award and who have been successfully appraised in an evaluation of their work.
In this year’s evaluation, doctors Ruth M. Risueño, Mayka Sánchez and Tanya Vavouri, fromthe IJC, have been awarded €100,000 funding for three years, which will help cover the salary of the group leader.
Dr. Ruth M. Risueño’s team is focussed on research into new therapies for leukaemic stem cells. Over these five years they have described three families of drugs which might potentially have an anti-leukaemic effect. As they identify them they will be able to study the signalling responsible for the survival of the leukaemic stem cells.
Knowing the biological basis that governs leukaemia makes it possible to widen the range of potentially effective therapeutic targets. Identifying new anti-leukaemia drugs in the laboratory enables the necessary preclinical studies to commence so that, in the near future, these drugs can be tried clinically.
Dr. Mayka Sánchez’s team is focussed on the study of iron metabolism. Although we only need small quantities of iron, it is essential for normal cell growth and for good health. Iron deficiency leads to anaemia, while iron overload leads to changes in the tissues leading to inflammation, cell death, organ dysfunction and, on occasion, cancer.
Dr. Sánchez’s group carries out research at different levels. One line of research concerns the mechanisms involved in iron metabolism and the genes that affect it. These studies could give rise to the discovery of new and rare iron metabolism diseases. Another line of research aims to design, improve and carry out new genetic tests to evaluate the iron in patients with malignant blood diseases.
Dr. Tanya Vavouri’s research is in the field of genetic regulation, epigenetics and chromatin. Her research group uses computational methods to analyse genomic data available, either from public databases, or which have been generated in cooperation with other research groups. They also study the drug decitabine, which is normally used for the treatment of certain patients with myelodysplastic syndromes. The drug alters the regulation of genes and consequently also cell function.
• Dr. Albert Oriol, a hematologist at the Catalan Institute of Oncology/Germans Trias i Pujol Hospital, and researcher at the Josep Carreras Leukaemia Research Institute, takes part in an international study to assess a promising combination of drugs in the treatment of multiple myeloma.
• Multiple myeloma is still an incurable disease, but progress made over the last ten years has led to a very considerable improvement in the range of available treatments to combat it. One of these promising drugs is called daratumumab.
• In Spain there are 40 new cases of multiple myelomaper million inhabitants each year.
El 25 de octubre se conmemora en todo el mundo el Día de los Síndromes Mielodisplásicos (SMD). Cada año en nuestro país más de 2.000 personas son diagnosticadas de SMD, un tipo de cáncer de la sangre, de momento difícilmente curable.
Como en ocasiones anteriores, la Fundación Josep Carreras ha colaborado en la edición del Manual de Trasplante Hematopoyético 2016, elaborado por el Dr. Enric Carreras, director médico de nuestra organización, junto con muchos otros colaboradores especialistas de diferentes centros de todo el país.
Leukos Biotech, a biotechnology company founded by the Josep Carreras Leukemia Research Institute and by Dr. Ruth M. Risueño will develop a novel class of drugs around a newly discovered therapeutic target that selectively destroys Leukemia Stem Cells.
The third Saturday of each month of September we celebrate the World Blood Donor Day Marrow and Umbilical Cord Blood, an initiative of the World Marrow Donors Association (WMDA). Its a day to remind citizens around the world about the importance of donating bone marrow (hematopoietic stem cell or blood stem cells). (Available in Spanish).
On September 15th we celebrate the World Lymphoma Awareness Day. Is an important day becauselymphomas are the most common type of blood cancer. It is estimated that in Spain each year about 7,000 new cases are diagnosed. (more info in Spanish)
Raul Torres is a member of one of our research groups in our Campus Clínic-UB of the Josep Carreras Leukaemia Research Institute. He just received a support of the “Lady Tata Memorial Trust” to continue his project in our center. We want to know a little more about him and his work …
I want to receive the latest news
(+34) 93 414 55 66
Contact
Espacio socios y amigos
